U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C5H6NO3.Zn
Molecular Weight 321.621
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC PIDOLATE

SMILES

[Zn++].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]2CCC(=O)N2

InChI

InChIKey=OWVLYQRCCIEOPF-QHTZZOMLSA-L
InChI=1S/2C5H7NO3.Zn/c2*7-4-2-1-3(6-4)5(8)9;/h2*3H,1-2H2,(H,6,7)(H,8,9);/q;;+2/p-2/t2*3-;/m00./s1

HIDE SMILES / InChI

Molecular Formula C5H6NO3
Molecular Weight 128.106
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Zinc Pidolate (Zinc PCA) is a topical skin product with purifying, astingent, anti-inflammatory, antiseptic activity. It has long been used as a cosmetic ingredient, because of its astringent and anti-microbial properties. Zinc Pidolate has also being shown to be effective against halitosis. Zinc PCA prevents the UV-induced MMP-1 production in vitro by suppressing the activation of AP-1. Zinc PCA was also able to enhance type I collagen synthesis in NHDFs, by increasing the expression of the mRNA encoding the ascorbic acid transporter SVCT2 in non-UV irradiated NHDFs, which suggests its promising effect against not only photoaged skin but also for the simple atrophic change of intrinsic skin ageing. Zinc PCA is able to suppress sebum secretion by inhibiting 5-α reductase in hyperseborrhea, to suppress body odor by forming zinc salts with short-chain fatty acids, to suppress wrinkles by inhibiting AP-1 to and inhibit bacterial growth including acne related Propionibacterium acnes.

CNS Activity

Curator's Comment: Known to penetrate blood-brain barrier in rats. Is produced naturally in human brain

Originator

Sources: Haitinger, L.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
CLEANSING FOAMING GEL ACNE PRO SKIN- zinc pidolate gel

Approved Use

Lange Gel will turn into foam, during application. It will cleanse skin thoroughly without any dryness effect, in order to avoid hyperseboohea phenomenon, a main cause of acne.

Launch Date

2012
Primary
Unknown

Approved Use

Unknown
Primary
EcoCare™ Zinclean

Approved Use

Use in anti-dandruff shampoos
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Fast analysis of water samples for detection of anions by capillary zone electrophoresis.
2001
Chromosome 13 dementia syndromes as models of neurodegeneration.
2001 Dec
Massive 5-oxoprolinuria with normal 5-oxoprolinase and glutathione synthetase activities.
2001 Jun
Expression and prognostic significance of lysozyme in male breast cancer.
2002
Comparison of the positive and negative ion electrospray mass spectra of some small peptides containing pyroglutamate.
2002
Complete structure of an increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom. ICPP is angiogenic via vascular endothelial growth factor receptor signalling.
2002 Aug 16
Conformationally restricted TRH analogues: constraining the pyroglutamate region.
2002 Feb
The primary structure of cassowary (Casuarius casuarius) goose type lysozyme.
2002 Jan
Stereoselective total syntheses of the racemic form and the natural enantiomer of the marine alkaloid lepadiformine via a novel N-acyliminium ion/allylsilane spirocyclization strategy.
2002 Jun 14
Pseudopeptide foldamers: the homo-oligomers of pyroglutamic acid.
2002 Jun 3
Five- and six-membered ring opening of pyroglutamic diketopiperazine.
2002 Mar 22
[Effect of a drug composition containing pyroglutamic acid and pyrrolidone on the cerebral circulation].
2002 May-Jun
Determination of the post-translational modifications of salivary acidic proline-rich proteins.
2003 Apr
Beta-lactams as versatile synthons for homochiral ibotenate analogues with potential for activity at glutamate receptors.
2003 Aug 7
Solution structure of the cytotoxic RNase 4 from oocytes of bullfrog Rana catesbeiana.
2003 Feb 28
Characterization of a new bradykinin-potentiating peptide (TmF) from Trimeresurus mucrosquamatus.
2003 Jul
Proinsulin C-peptide and its C-terminal pentapeptide: degradation in human serum and Schiff base formation with subsequent CO2 incorporation.
2003 May
[Characteristics of pyrrolidone pharmacokinetics in rats].
2003 Nov-Dec
Structural characterization of native mouse zona pellucida proteins using mass spectrometry.
2003 Sep 5
Glutamine in commercial liquid nutritional products.
2004 Aug 11
Stabilization of peptide guinea pig myelin basic protein 72-85 by N-terminal acetylation-implications for immunological studies.
2004 Feb
Expression, purification, and characterization of avian Thy-1 from Lec1 mammalian and Tn5 insect cells.
2004 Feb
Chemical characterization of a lambda I amyloid protein isolated from formalin-fixed and paraffin-embedded tissue sections.
2004 Mar
Mass spectrometric analysis of posttranslational modifications of a carrot extracellular glycoprotein.
2004 May 25
Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH(2)).
2004 Sep
Mass spectrometry analysis of recombinant human ZP3 expressed in glycosylation-deficient CHO cells.
2004 Sep 28
A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition.
2005
The computer modelling of human TRH receptor, TRH and TRH-like peptides.
2005
Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
2005 Apr
Nanoparticles on the basis of highly functionalized dextrans.
2005 Aug 3
Acetaminophen-induced anion gap metabolic acidosis and 5-oxoprolinuria (pyroglutamic aciduria) acquired in hospital.
2005 Jul
Preparation and reactivity of aminoacyl pyroglutamates. Facile synthesis of 10-membered-ring cyclic dipeptides derived from 1,4-diaminobutyric and glutamic acids.
2005 Mar
Biomarker metabolites capturing the metabolite variance present in a rice plant developmental period.
2005 May 31
Cloning, expression, characterization, and crystallization of a glutaminyl cyclase from human bone marrow: a single zinc metalloenzyme.
2005 Sep
CFSUM1 and CFSUM2 in urine from patients with chronic fatigue syndrome are methodological artefacts.
2006 Feb
Zinc l-pyrrolidone carboxylate inhibits the UVA-induced production of matrix metalloproteinase-1 by in vitro cultured skin fibroblasts, whereas it enhances their collagen synthesis.
2012 Feb
Patents

Sample Use Guides

In Vivo Use Guide
Sources: Topical, as a compontent of lotions, creams and other cosmetic products.
Topical, as a compontent of lotions, creams and other cosmetic products.
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:13:39 GMT 2023
Edited
by admin
on Fri Dec 15 19:13:39 GMT 2023
Record UNII
C32PQ86DH4
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC PIDOLATE
WHO-DD  
Common Name English
ZINC PCA
INCI  
INCI  
Official Name English
ZINC, BIS(5-OXO-L-PROLINATO)-
Common Name English
ZINC PCA [INCI]
Common Name English
ZINC PYRROLIDONE CARBOXYLATE
Common Name English
ZINC PYRROLIDONECARBOXYLATE
Common Name English
ZINC PYROGLUTAMATE
Common Name English
ZINC L-PYROGLUTAMATE
Common Name English
PROLINE, 5-OXO-, ZINC SALT (2:1), L-
Common Name English
Zinc Pidolate [WHO-DD]
Common Name English
Code System Code Type Description
PUBCHEM
11602214
Created by admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
PRIMARY
DAILYMED
C32PQ86DH4
Created by admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
PRIMARY
EVMPD
SUB26632
Created by admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
PRIMARY
EPA CompTox
DTXSID40935009
Created by admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
PRIMARY
CAS
15454-75-8
Created by admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
PRIMARY
DRUG BANK
DBSALT001565
Created by admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
PRIMARY
SMS_ID
100000090155
Created by admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
PRIMARY
RXCUI
1426280
Created by admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
PRIMARY RxNorm
FDA UNII
C32PQ86DH4
Created by admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
PRIMARY
ECHA (EC/EINECS)
239-473-5
Created by admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE